Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;14(2):147-56.
doi: 10.2174/1389202911314020007.

Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment

Affiliations

Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the Treatment

Paolo Bosco et al. Curr Genomics. 2013 Apr.

Abstract

Late-onset Alzheimer's disease (LOAD) is the most common form of dementia in the elderly. LOAD has a complex and largely unknown etiology with strong genetic determinants. Genetics of LOAD is known to involve several genetic risk factors among which the Apolipoprotein E (APOE) gene seems to be the major recognized genetic determinant. Recent efforts have been made to identify other genetic factors involved in the pathophysiology of LOAD such as genes associated with a deficit of neurotrophic factors in the AD brain. Genetic variations of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), and transforming-growth-factor-β1 (TGF-β1) are known to increase the risk to develop LOAD and have also been related to depression susceptibility in LOAD. Transforming-Growth-Factor-β1 (TGF-β1) is a neurotrophic factor that exerts neuroprotective effects against ß-amyloid-induced neurodegeneration. Recent evidence suggests that a specific impairment in the signaling of TGF-β is an early event in the pathogenesis of AD. TGF-β1 protein levels are predominantly under genetic control, and the TGF-β1 gene, located on chromosome 19q13.1-3, con-tains several single nucleotide polymorphisms (SNPs) upstream and in the transcript region, such as the SNP at codon +10 (T/C) and +25 (G/C), which is known to influence the level of expression of TGF-β1. In the present review, we summarize the current literature on genetic risk factors for LOAD, focusing on the role of the TGF-β1 gene, finally discussing the possible implications of these genetic studies for the selection of patients eligible for neuroprotective strategies in AD.

Keywords: Alzheimer’s disease; Depression; Drugs; Genetic polymorphism; Risk factor; Transforming-growth-factor-β1..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hardy J. The amyloid hypothesis for Alzheimer's disease a critical reappraisal. J. Neurochem. 2009;110(4):1129–1134. - PubMed
    1. Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia importance and treatment considerations. Int. Rev. Psychiatry . 2008;20(4):396–404. - PubMed
    1. Fang Y, Zhang L, Zeng Z, Lian Y, Jia Y, Zhu H, Xu Y. Promoter polymorphisms of serpine1 are associated with the antidepressant response to depression in Alzheimer's disease. Neurosci. Lett. 2012;516(2):217–220. - PubMed
    1. Combarros O, Alvarez-Arcaya A, Oterino A, Berciano J, Delgado-Rodríguez M, Peña N, Fernández-Viadero C, Pérez-López LJ, Setién S, Carvajal A. Polymorphisms in the presenilin 1 and presenilin 2 genes and risk for sporadic alzheimer’s disease. J. Neurol. Sci. 1999;171(2):88–91. - PubMed
    1. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone CM, Gobbi M, Colombo L, Bastone A, Beeg M, Manzoni C, Francescucci B, Spagnoli A, Cantù L, Del Favero E, Levy E, Salmona M, Tagliavini F. A recessive mutation in the APP gene with dominant- negative effect on amyloidogenesis. Science . 2009;323(5920):1473–1477. - PMC - PubMed

LinkOut - more resources